Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment
ConditionActinic Keratoses
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCosmetique Active International
About this trial
This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria. The purpose of the study is to evaluate a holistic management (efficacy, tolerability and lesion cosmetic outcomes) of Tolak® treatment.
Eligibility criteria
Qualifiers
diagnosis of at least 4 non-hypertrophic, non-hyperkeratotic actinic keratosis of the the scalp
planned treatment of actinic keratoses of the scalp with Tolak®
Olsen grade I or II
Disqualifiers
known or documented intolerance to any of the ingredients of Tolak® or Lipikar Urea 30%
treatment of actinic keratoses in the treatment area within the past 3 months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.)
suspected invasive squamous cell cancer in the treatment area
chronic wounds, erosions, pre-existing inflamed or infected skin with disruption of the epidermal barrier in the treatment area current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-Fluorouracil
Trial design
Treatments tested in this trial
- Group A: holistic approach
- Group B: Tolak® Standard of use
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov